Figure 4. PKRA7 enhances the efficacy of chemotherapeutic drugs to reduce glioblastoma and pancreatic xenograft tumor growth.

(A) Kaplan-Meier curve of nude mice after temozolomide and PKRA7 treatment following IC injection of 1×10⁴ D456MG cells. Treatment with 10 mg/kg temozolomide or control started 3 days after IC injection for a total of 5 consecutive daily treatments. Treatment with PKRA7 or control started 7 days after IC injection and continued for the duration of experiment. 5 mice per condition. (B) AsPc-1 cells were SC injected into nude mice, and control (n = 10) or PKRA7 (n = 10) treatment was commenced when tumors were visible (7 days). Treatment with 100 mg/kg gemcitabine (n = 10) or control (n = 10) started 7 days after tumor implantation and was administered every 4 days for two weeks for a total of 4 treatments (#). Measurements were taken every 3 days. 5 mice per condition. (C) Average tumor weight of control, gemcitabine, PKRA7 and gemcitabine plus PKRA7-treated mouse tumors after their removal (*p≤0.05).